六味五灵片联合替比夫定治疗慢性乙型肝炎肝纤维化疗效分析

目的：观察六味五灵片联合替比夫定（ LdT）治疗慢性乙型肝炎（ CHB）肝纤维化的临床疗效。方法：将120例CHB肝纤维化患者随机分为观察组和对照组。观察组（64例）患者口服六味五灵片和LdT，对照组（56例）患者单用LdT，疗程均为24周。比较两组患者治疗前后的临床症状、肝功能及肝纤维化指标变化情况。结果：治疗24周后，观察组患者ALT、 AST、 TBil分别为（25.4±16.3） U/L、（28.4±15.9） U/L、（22.8±10.7）μmol/L，均明显低于对照组（44.7±19.6） U/L、（40.1±17.1） U/L、（35.2±11.5）μmol/L ，差异有显著性意义（ P＜0.05）。治疗后两组患者肝纤维化指标均显著下降，且观察组下降幅度优于对照组（P＜0.05）。结论：六味五灵片联合LdT能够明显改善CHB肝纤维化患者的肝功能，促进HBV DNA转阴，同时还能显著降低患者的血清肝纤维化指标，提高临床疗效。

Curative effect analysis for Liuweiwuling tablets combined with telbivudine in treating chronic hepatitis B fibrosis

Objective： To observe the clinical effect of Liuweiwuling tablets combined with telbivudine in treatment of hepa-titis B liver fibrosis.Methods： One hundred and twenty cases of chronic hepatitis B （ CHB） patients with fibrosis were randomly divided into two groups：the observation group and the control group.The observation group of 64 cases received Liuweiwuling tablets and oral telbivudine;the control group of 56 cases received simple oral telbivudine.The changes of clinical symptoms, liver function and index hepatic fibrosis of the two groups were observed before and after treatment.Results： After 24 weeks′treatment, the value of ALT, AST and TBil of the observation group [respectively, （25.4 ±16.3） U/L, （28.4 ±15.9） U/L, （22.8 ±10.7） μmol/L] were all lower than the control group [respectively, （44.7 ±19.6） U/L, （40.1 ±17.1） U/L, （35.2 ±11.5） μmol/L, P〈0.05] and the difference was statistically significant （P〈0.05） .And the index hepatic fibrosis of both groups was all reduced after treatment, while the reduction of the observation group was significantly higher than the con-trol group.Conclusion： The therapy of Liuweiwuling tablets combined with telbivudine in treatment of CHB fibrosis can improve liver function and promote negative conversion of HBV DNA, meanwhile, it can also decrease the serum liver fibrosis indexes and increase the treatment effect.